Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
NCT Number: NCT02857374
This pilot clinical trial studies intravital microscopy in identifying tumor vessels in patients with stage IB-IIIC melanoma undergoing sentinel lymph node biopsy. By examining sentinel lymph nodes through intravital microscopy before they are removed, doctors may learn specific information regarding how melanoma may spread to lymph nodes and other sites of the body.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Buffalo, New York, 14263, United States
PRIMARY OBJECTIVES:
I. To determine the feasibility of intravital microscopy in characterizing the microvasculature of the sentinel lymph node (SLN) in melanoma patients requiring SLN biopsy.
SECONDARY OBJECTIVES:
I. To identify vascular blood flow parameters and flow kinetics associated with the sentinel lymph node vasculature and define the utility of using commonly used fluorescent agents during human intravital microscopy and correlate with clinical outcomes (time to recurrence, survival), as a potential basis for a novel prognostic tool and/or microstaging technique.
TERTIARY OBJECTIVES:
I. To determine the relationship between live microscopically-recorded images and pathology slides in terms of vessel density and vessel diameter.
OUTLINE:
Patients receive indocyanine green and fluorescein sodium injection intravenously (IV) and then undergo intravital microscopic observation over 15-20 minutes during standard of care sentinel node biopsy.
After completion of study treatment, patients are followed up at 3 weeks and then every 6 months for 5 years or every 3 months for 2 years and every 6 months for another 2 years.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Undergo intravital microscopy
Given IV
Other names: AK-Fluor, Fluorescite
Correlative studies
Undergo standard of care sentinel node biopsy
Other names: Sentinel Node Biopsy, Sentinel node biopsy alone, SLNB, SNB
Time frame: Up to 3 weeks
The visualization method will be deemed successful in patients with tumor vessel identification, measurement of tumor vessel diameters, determining vessel density, and visualizing fluorescein/indocyanine green within the tumor vessels.
Time frame: Up to 5 years
Sample sentinel lymph node characteristics obtained from the intervention will be characterized using descriptive statistics (means, medians) and 95% confidence intervals.
Time frame: Up to 5 years
Assessed using Kaplan Meier and Proportional Hazards methods. Collected through routine follow-up processes.
Time frame: Up to 5 years
Assessed using Kaplan Meier and Proportional Hazards methods. Collected through routine follow-up processes.
Time frame: Up to 5 years
Assessed using Logistic Regression. Collected through routine follow-up processes.
Time frame: Up to 3 weeks
Time frame: Up to 5 years
Sample sentinel lymph node characteristics obtained from the intervention will be characterized using descriptive statistics (means, medians) and 95% confidence intervals.
Time frame: Up to 5 years
The relationship between the live microscopically-recorded images and the pathology slides in terms of vessel density and vessel diameter will be determined. Correlations between microscopic observations (vessel diameter, density, blood flow velocity, vessel hierarchy tissue penetration of fluorescein/indocyanine green) with pathologic node positivity and clinical outcomes (time to recurrence, survival) will be analyzed.
Roswell Park Cancer Institute
Other
Intravital Microscopy (IVM) During Sentinel Lymph Node (SLN) Biopsy for Melanoma
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03028948
Melanoma, Neoplasms
New Brunswick, New Jersey, United States
View Trial DetailsNCT01886235
Melanoma, Neoplasms
Buffalo, New York, United States
View Trial DetailsNCT01460875
Melanoma, Neoplasms
Columbus, Ohio, United States
View Trial DetailsNCT01989559
Melanoma, Neoplasms
Portland, Oregon, United States
View Trial Details